These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

365 related items for PubMed ID: 15890721

  • 1. Influence of inoculum size of Staphylococcus aureus and Pseudomonas aeruginosa on in vitro activities and in vivo efficacy of fluoroquinolones and carbapenems.
    Mizunaga S, Kamiyama T, Fukuda Y, Takahata M, Mitsuyama J.
    J Antimicrob Chemother; 2005 Jul; 56(1):91-6. PubMed ID: 15890721
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa.
    Chin JN, Jones RN, Sader HS, Savage PB, Rybak MJ.
    J Antimicrob Chemother; 2008 Feb; 61(2):365-70. PubMed ID: 18079128
    [Abstract] [Full Text] [Related]

  • 9. Bacteriostatic and bactericidal activities of eight fluoroquinolones against MexAB-OprM-overproducing clinical strains of Pseudomonas aeruginosa.
    Dupont P, Hocquet D, Jeannot K, Chavanet P, Plésiat P.
    J Antimicrob Chemother; 2005 Apr; 55(4):518-22. PubMed ID: 15722391
    [Abstract] [Full Text] [Related]

  • 10. In-vitro investigation of the antibacterial activity of agents which may be used for the oral treatment of lung infections in CF patients.
    Richards RM, Hamilton VE, Thomas MR.
    J Antimicrob Chemother; 1998 Aug; 42(2):171-8. PubMed ID: 9738834
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004.
    DeRyke CA, Kuti JL, Nicolau DP.
    Pharmacotherapy; 2007 Mar; 27(3):333-42. PubMed ID: 17316145
    [Abstract] [Full Text] [Related]

  • 12. Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
    Seral C, Barcia-Macay M, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F.
    J Antimicrob Chemother; 2005 Apr; 55(4):511-7. PubMed ID: 15731197
    [Abstract] [Full Text] [Related]

  • 13. Newer carbapenems for urinary tract infections.
    Matsumoto T, Muratani T.
    Int J Antimicrob Agents; 2004 Sep; 24 Suppl 1():S35-8. PubMed ID: 15364304
    [Abstract] [Full Text] [Related]

  • 14. Moxifloxacin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro.
    Ulrich M, Berger J, Möller JG, Döring G.
    Infection; 2005 Dec; 33 Suppl 2():50-4. PubMed ID: 16518712
    [Abstract] [Full Text] [Related]

  • 15. Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.
    Zinner SH, Vostrov SN, Alferova IV, Lubenko IY, Portnoy YA, Firsov AA.
    Int J Antimicrob Agents; 2004 Aug; 24(2):173-7. PubMed ID: 15288317
    [Abstract] [Full Text] [Related]

  • 16. The effectiveness of two ciprofloxacin formulations for experimental Pseudomonas and Staphylococcus keratitis.
    Engel LS, Callegan MC, Hill JM, Folkens AT, Shimomura Y, O'Callaghan RJ.
    Jpn J Ophthalmol; 1996 Aug; 40(2):212-9. PubMed ID: 8876389
    [Abstract] [Full Text] [Related]

  • 17. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT, Tessier PR, Li C, Nightingale CH, Nicolau DP.
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vitro postantibiotic effect of imipenem and enoxacin alone and in combination against Pseudomonas aeruginosa.
    Hostacká A.
    Pharmazie; 1997 Jul; 52(7):544-6. PubMed ID: 9266592
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.